Overview

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Status:
Completed
Trial end date:
2019-08-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company